Schering Aktiengesellschaft

Bayer Pharma Aktiengesellschaft

Bayer Schering Pharma Ag

Bayer Oy

Bayer Intellectual Property Gmbh

Ulrike Fuhrmann

Wolfgang Schwede

Arwed Cleve

Martin Schneider

Ulrich Klar

Gunter Neef

Kristof Chwalisz

Bernhard Lindenthal

Holger Heb-Stumpp

Heikki Lyytikäinen

Norbert Schmees

Harri Jukarainen

Peter Serno

Jyrki Pihlaja

Manja Ahola

Ina Gröticke

Bernd Duesterberg

Satu Kleemola

Anja Schmidt

Tero Parkatti

Tuula Valo

Carsten Moeller

Gerhard Siemeister

Rolf Bohlmann

Bernd Buchmann

Dieter Bittler

Karl-Heinrich Fritzemeier

Anne Mengel

Andrea Rotgeri

Orlin Petrov

Ulrich Bothe

Rosemarie Lichtner

Christa Hegele-Hartung

Jens Hoffmann

Hans-Peter Muhn

Peter Esperling

Manfred Lehmann

Nico Bräuer

Antonius Ter Laak

Hermann Kuenzer

Antje Rottmann

Ulrike Röhn

Steffen Borden

Katja Prelle

Stefan Pruehs

Peter Muhn

Gunnar Garke

Margarete Brudny-Kloeppel

Rainer Hasselmann

Marcus Schultze-Mosgau

Michael Klotzbuecher

Katrin Waellnitz

Stefanie Lindemann

The invention relates to a method for contraception and for reducing menstrual problems and inducing amenorrhea, wherein an intrauterine delivery device is used for the controlled release of a combination of progestogen or a drug having a progestogenic activity and at least one therapeutically active substance capable of preventing or suppressing abnormal and/or irregular endometrial bleeding over a prolonged period of time.

Intrauterine delivery system for contraception

The invention relates to a pharmaceutical composition for non-hormonal, on-demand contraception and to processes for preparing this pharmaceutical composition. The latter comprises 2H-indazole as novel EP2 receptor antagonists in combination with COX inhibitors. The invention furthermore provides a method for non-hormonal female-controlled on-demand contraception where a pharmaceutical composition comprising EP2 receptor antagonists in combination with COX inhibitors is taken on demand prior to expected sexual intercourse.

Pharmaceutical composition and the use thereof, and application regime of said pharmaceutical composition for on-demand contraception

The invention relates to a method of hormonal female controlled 'on demand' contraception, in which a pharmaceutical preparation comprising a COX inhibitor and levonorgestrel is taken on demand prior to expected sexual intercourse. Further subjects of the invention relate to pharmaceutical compositions and application regimes for 'on demand' contraception.

Use and application regimen of a pharmaceutical composition containing levonorgestrel and a COX inhibitor for on-demand contraception

A 18-Methyl-19-nor-17-pregn-4-ene-21,17-carbolactone of general formula I 

18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceutical preparations that contain the latter

The present invention relates to progesterone receptor antagonists of general formula I: in which R1 can be a hydrogen atom and R2 a hydroxyl group or R1 and R2 together can be an oxo group.

Progesterone receptor antagonists

This invention relates to nonsteroidal progesterone receptor modulators of general formula I, a process for their production, the use of progesterone receptor modulators for the production of pharmaceutical agents as well as pharmaceutical compositions that contain these compounds. The compounds according to the invention are suitable for therapy and prophylaxis of gynecological diseases, such as endometriosis, leiomyomas of the uterus, dysfunctional bleeding and dysmenorrhea, as well as for the therapy and prophylaxis of hormone-dependent tumors and for use for female birth control as well as for hormone replacement therapy.

Nonsteroidal progesterone receptor modulators

The present invention relates to non-steroidal progestins of the general formula (I) wherein or a pharmaceutically acceptable derivative or analogue thereof. These progestins are suitable for selectively modulating progesterone receptor mediated effects in different target tissues, particularly in uterine tissue versus breast tissue. Therefore, the progestins of the present invention, optionally in combination with estrogens, may be used for contraception (in particular in estrogen-free oral contraceptives), hormone replacement therapy and the treatment of gynecological disorders. The present invention furthermore relates to methods for selectively modulating progesterone receptor mediated effects in different target tissues or organs.

Non-steroidal progesting

The present invention relates to methods and uses for preventing or treating hormone-dependent disease, in particular breast cancer, in a mammal by antiprogestins, in particular antiprogestin 11&#x3b2;-(4-acetylphenyl)-17&#x3b2;-hydroxy-17&#x3b1;-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue thereof. The invention further relates to pharmaceutical compositions comprising said antiprogestin.

Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases

This invention describes the new 17&#x3b1;-fluoroalkyl steroids of general formula I as well as their physiologically compatible salts with bases. The new compounds have an extraordinary strong antigestagenic action and are suitable for the production of pharmaceutical preparations.

Antigestagenically active steroids with a fluorinated 17&#x3b1;-alkyl chain

Antigestagenically active steroids with a fluorinated 17-alpha-alkyl chain

Antigestagenically active steroids with a fluorinated 17&agr;-alkyl chain

This invention describes the new 17&agr;-fluoroalkyl steroids of general formula I

Antigestagenically active steroids with a flourinated 17 &agr;-alkyl chain

Growing community of inventors

Berlin, Germany

Ulrike Fuhrmann